CLINICAL AND PARACLINICAL CHARACTERISTICS OF CHRONIC URTICARIA
Main Article Content
Abstract
Background: Chronic urticaria (CU) affects approximately 1% of the population worldwide. CU can have a strong impact on quality of life (QOL), work, family and society. The etiology and pathogenesis of CU are complex. Currently, in Vietnam, there are not many studies on CU. Therefore, we conducted this study. Objective: Describe clinical and paraclinical characteristics in patients with chronic urticaria. Methods: Cross-sectional study describing 112 CU patients examined and treated at Can Tho City Dermatology Hospital from June 2023 to December 2023. The patients' medical history was collected and clinical examination was performed, and paraclinical tests were performed at Can Tho City Dermatology Hospital. Results: 112 patients with chronic urticaria with 47 men and 65 women, average age was 25.1±18.0 years. Symptoms of edema and itching appeared in 100% of patients, angioedema accounted for 9, 8%, nausea 6.3%, fever 4.5%, abdominal pain 1.8%. The disease activity score (UAS) had a median of 4.6[2;6]. Quality of life score in CU patients (CU-Q2oL) has a median of 96.7 [68;110]. Conclusion: CU is a common disease with complex etiology, greatly affecting the patient's health and quality of life. Identifying and eliminating disease-causing allergens and avoiding re-exposure to allergens is the best way to treat and prevent disease. The disease is more common in women than men, has an early onset, and is most common at the age of <18 years. The median UAS score was 4.6[2;6]. The median CU-Q2oL score was 96.7 [68;110]. Hematology tests in CU are usually within normal limits.
Article Details
Keywords
Chronic urticaria, clinical and paraclinical characteristics, UAS, CU-Q2oL.
References
2. Sánchez-Borges M et al (2017), " Review of Physical Urticarias and Testing Methods". Curr Allergy Asthma Rep. 17(8):51.
3. Wood RA, Khan DA et al (2019), American Academy of Allergy, Asthma and Immunology response to the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of Urticaria 2017 revision. Allergy. 74(2):411-413.
4. Goncalo et al (2021),”Journal of Dermatology The global burden of chronic urticaria for the patient and society”. British Journal of Dermatology 184(2): 226–236.
5. Nguyễn Tiến Dũng (2020), “Bệnh mày đay”. Hướng dẫn chẩn đoán và điều trị các bệnh Da Liễu. (3): 149-153.
6. Nguyễn Hoàng Vân (2022), “Đánh giá hiệu quả điều trị bệnh mày đay mạn tính bằng levocetirizin liều 10mg”, Bệnh viện Trung ương Quân đội 108, 17(6): 18-2
7. Lê Thái Vân Thanh (2023), "Nồng độ tnf-alpha huyết thanh trên bệnh nhân mày đay mạn tính". Tạp chí Y học Việt Nam. 535 (2), 353-357.
8. Ngô Thị Hồng Hạnh (2023), “Đặc điểm lâm sàng và cận lâm sàng của bệnh mày đay mạn tính cảm ứng”, Tạp chí Y Học Việt Nam, 527(1B); 26-30.
9. Zuberbier T., Asero R., Bindslev-Jensen C. et al. (2009), "EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria". Allergy. 64(10): 1417-1426.
10. Zuberbier T., Aberer W., Asero R. et al. (2014), "The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update". Allergy. 69(7): 868-887